Of interest, several mouse studies have shown that EREG deficiency resulted in reduced lung tumor promotion, and EREG overexpression fueled an oncogenic feedback loop that activated signaling pathways downstream of EGFR/ErbB4, suggesting that EREG might be a therapeutic target in non-small-cell lung carcinoma (NSCLC) 7,8. The gene discussed is EREG; the disease is non-small cell lung carcinoma.